Skip to main content

Table 2 Antimicrobial resistance of Escherichia coli isolates to the tested antibiotics

From: Shifting trends in bacteriology and antimicrobial resistance among gastrointestinal fistula patients in China: an eight-year review in a tertiary-care hospital

Resistance rate (%)
Isolate/Antibiotics 2008–2011 2012–2015 Total P for Trend Test
All Escherichia coli
 AMK 7.78 14.16 11.33 0.154
 AMP 97.92 96.49 97.14 0.537
 SAM 81.97 87.93 85.88 0.279
 TZP 23.47 25.00 24.30 0.795
 CZO 92.55 91.30 91.87 0.742
 CAZ 81.82 69.83 75.35 0.042
 FEP 75.51 62.07 68.22 0.035
 IPM 14.29 25.86 20.56 0.037
 CIP 90.16 79.13 82.95 0.064
ESBL+
 AMK 6.78 12.33 9.85 0.287
 AMP 100.00 100.00 100.00
 SAM 77.78 93.15 88.07 0.020
 TZP 20.31 6.85 13.14 0.020
 SXT 84.21 73.61 77.27 0.207
 CZO 100.00 100.00 100.00
 CAZ 89.23 68.49 78.26 0.003
 FEP 81.25 60.27 70.07 0.007
 IPM 12.31 8.22 10.14 0.427
 CIP 86.11 80.82 82.57 0.494
ESBL-
 AMK 6.67 16.22 13.46 0.361
 AMP 88.24 89.74 89.29 0.867
 SAM 77.78 77.50 77.55 0.986
 ZP 35.29 57.50 50.88 0.125
 SXT 88.89 67.50 71.43 0.199
 CZO 58.82 74.36 69.64 0.245
 CTT 28.57 70.00 63.83 0.035
 CAZ 52.94 70.00 64.91 0.217
 FEP 52.94 62.50 59.65 0.501
 IPM 43.75 57.50 53.57 0.351
 CIP 88.89 77.50 79.59 0.444
Not all tested antibiotics are listed
  1. AMK Amikacin, AMP Ampicillin, SAM Ampicillin/Sulbactam, CAZ Ceftazidime, efepime, CTT Cefotetan, CZO Cefazolin, IPM Imipenem, TZP Piperacillin-Tazobactam, CIP Ciprofloxacin
  2. Data in boldface reflected p values < 0.05